8-K: 60 Degrees Pharmaceuticals Receives Ethics Approval for Babesiosis Study, Aiming to Repurpose Malaria Drug

60 Degrees Pharmaceuticals has announced ethics approval for an expanded access study of tafenoquine for babesiosis, aiming to confirm promising results from a previous case series.

Summary

• 60 Degrees Pharmaceuticals has received ethics approval for an open-label study of tafenoquine, combined with standard care, to treat babesiosis in immunocompromised patients.
• The study aims to validate an 80% cure rate observed in a prior Yale School of Public Health case series using tafenoquine in similar patients.
• Tafenoquine, marketed as ARAKODA for malaria prophylaxis, is being investigated for babesiosis treatment, though it is not yet FDA-approved for this use.
• Babesiosis, a tick-borne illness, is increasing, particularly in the Northeast, and can be life-threatening, especially for the elderly and immunocompromised.
• The company is conducting three studies to address different patient populations: hospitalized patients, those with persistent disease, and individuals with chronic babesiosis.
• 60 Degrees Pharmaceuticals plans to file a New Drug Application with the FDA in the second quarter of 2026 for a supplemental indication for tafenoquine in babesiosis.
• The company estimates a total accessible market of 38,000 acute patients and at least 375,000 chronic babesiosis patients in the U.S. through 2035, in addition to 1.7 million potential malaria prophylaxis users.

Sentiment

Score: 7

Explanation: The document is generally positive due to the ethics approval and promising initial results, but there are risks and uncertainties associated with clinical trials and regulatory approvals.

Positives

• Ethics approval for the expanded access study is a significant step forward in the development of tafenoquine for babesiosis.
• The 80% cure rate observed in the Yale case series is a promising indicator of potential efficacy.
• The company is addressing a growing unmet medical need with a focus on multiple patient populations.
• The potential market size for babesiosis treatment is substantial, with an estimated 38,000 acute and at least 375,000 chronic patients.
• The company has a clear timeline for FDA submission in the second quarter of 2026.

Negatives

• Tafenoquine is not yet FDA-approved for babesiosis treatment.
• The 80% cure rate from the Yale study was based on a small sample size of only five patients, with a wide confidence interval of 30-100%.
• The company has no manufacturing capacity which puts them at risk of lengthy and costly delays of bringing their products to market.
• The company is reliant on third parties for manufacturing.

Risks

• The company may not be able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine.
• The company may not be able to successfully conduct planned clinical trials.
• There is substantial doubt as to the company's ability to continue on a going-concern basis.
• The company might not be eligible for Australian government research and development tax rebates.
• The company has no manufacturing capacity which puts them at risk of lengthy and costly delays of bringing their products to market.

Future Outlook

The company plans to file a New Drug Application with the FDA in the second quarter of 2026 for a supplemental indication for tafenoquine in babesiosis and is conducting market research and epidemiological studies to further refine market estimates.

Management Comments

• Tafenoquine is showing exciting promise in addressing babesiosis within various human patient populations, said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow, PhD.
• We are moving quickly in an effort to confirm Yales observations while advancing the clinical program for hospitalized babesiosis patients which is now enrolling at Tufts Medical Center.
• Ultimately, we aim to re-purpose tafenoquine as a new babesiosis treatment.

Industry Context

This announcement is significant as it addresses the rising incidence of babesiosis, a tick-borne illness, and seeks to repurpose an existing drug, tafenoquine, for a new indication. This approach aligns with the industry trend of exploring new uses for existing drugs to address unmet medical needs.

Comparison to Industry Standards

• The 80% cure rate observed in the Yale case series is promising, but it is based on a small sample size of five patients, which is not a robust benchmark compared to larger clinical trials.
• The company is using an expanded access program, which is a common approach for investigational drugs in serious conditions where no alternative treatment is available, similar to other companies developing treatments for rare diseases.
• The company's plan to file a New Drug Application in 2026 is a typical timeline for drug development, but the success of the application will depend on the results of the ongoing clinical trials.
• The estimated market size of 38,000 acute and at least 375,000 chronic babesiosis patients is a significant opportunity, but the actual market penetration will depend on the efficacy and safety of tafenoquine and the competitive landscape.

Stakeholder Impact

• Shareholders may see potential for increased value if the clinical trials are successful and the drug is approved.
• Patients with babesiosis, especially those who are immunocompromised, may benefit from a new treatment option.
• Employees of 60 Degrees Pharmaceuticals will be involved in the clinical trials and regulatory processes.
• The company's suppliers and partners may see increased business opportunities if the drug is successful.

Next Steps

• Continue enrollment in the clinical trial of tafenoquine for babesiosis at Tufts Medical Center.
• Conduct the expanded access study to confirm the findings of the Yale School of Public Health case series.
• Plan an expanded access study for chronic babesiosis, gated by an ongoing epidemiological study.
• File a New Drug Application with the FDA in the second quarter of 2026 for a supplemental indication for tafenoquine in babesiosis.

Key Dates

Keywords

tafenoquine, babesiosis, ARAKODA, clinical trial, FDA, infectious diseases, immunocompromised, malaria, expanded access, orphan disease